What to look for when Deere & Company (DE) reports Q4 2025 results

When Deere & Company (NYSE: DE) reports its fourth-quarter results next week, investors will be watching for updates on equipment demand and production trends. While tariff-related uncertainties and weak farmer confidence remain a drag on sales and profitability, the company maintained decent margins this year.

Q4 Report on Tap

The Illinois-headquartered manufacturer of agricultural and construction equipment is set to unveil its fourth-quarter financial data on Wednesday, November 26, at 6:25 am ET. On average, analysts following the company predict earnings of $3.83 per share for the October quarter, representing a sharp decline from the year-ago quarter when it earned $4.55 per share. Meanwhile, Q4 revenues are expected to grow 5.75% year-over-year to $9.81 billion.

After hitting an all-time high in May, Deere’s stock has dropped around 10%. The average stock price for the past twelve months is $476.67. Recently, the stock rebounded and has maintained the momentum ahead of next week’s earnings.

Also Read: A snapshot of Deere & Company’s Q3 2025 earnings report

Weak Q3

In the third quarter, net income declined to $1.29 billion or $4.75 per share from $1.73 billion or $6.29 per share in the corresponding quarter of FY24. The weak bottom-line performance reflects a 9% decline in Q3 sales to $12.01 billion. Both sales and profit exceeded Wall Street’s expectations, continuing the long-term trend of outperformance. The management said it expects net income for fiscal 2025 to be in the range of $4.75 billion to $5.25 billion.

From Deere & Company’s Q3 2025 Earnings Call:

“After a slow start to the year, turf and compact utility tractor shipments in North America were better than expected, reflecting improvement in consumer confidence and favorable weather conditions. Year-over-year retail sales also increased for both tractors in Europe and Earthmoving and Forestry equipment in North America, reversing several quarters of flat or declining sales. Amidst this backdrop, Deere’s performance continues to demonstrate strong financial results.”

Strategy

As part of its efforts to empower customers, Deere is using advanced technologies such as See & Spray and Harvest Settings Automation in its products, thereby significantly reducing input costs and boosting efficiency for users. Meanwhile, the management has cautioned of a $600 million pre-tax impact from new import tariffs in the current fiscal year. It has incurred around $300 million in tariff expenses in the first nine months of the year.

On Wednesday, the stock opened at $474.36 and traded slightly higher throughout the session. DE has gained 3.6% in the past 30 days, signaling a recovery from the downturn it experienced earlier.

The post What to look for when Deere & Company (DE) reports Q4 2025 results first appeared on AlphaStreet.

from NYSE Updates – Techyrack Hub https://ift.tt/ZmOpM40
via IFTTT

What to look for when Alibaba (BABA) reports Q2 FY26 results

Alibaba Group Holding Limited (NYSE: BABA) is expected to report mixed results for the second quarter, with analysts forecasting a modest increase in revenues and a decline in adjusted earnings. The core e-commerce business faces pressure from cautious consumer spending and economic uncertainties. Meanwhile, the company’s booming cloud business remains a key growth driver.

BABA had a positive start to 2025, and the stock has sustained that momentum so far. It has gained a whopping 89% since the beginning of the year, marking a strong recovery from the weakness experienced over the past few years. The stock recently hit a four-year high but reversed course in early November, trending lower ahead of next week’s earnings. Meanwhile, analysts are bullish and recommend buying the stock, citing its potential to grow up to 23% in the next twelve months.

Q2 Report Due

The China-based e-commerce behemoth is set to report second-quarter results on November 25, before the opening bell. Analysts’ consensus revenue estimate for the September quarter is RMB243.2 billion, compared to RMB236.5 billion in the corresponding period of fiscal 2025. Market watchers are looking for adjusted earnings of RMB5.78 per share for Q2. That compares to RMB15.06 per share the company earned in the year-ago quarter, which includes certain one-off gains.

From Alibaba’s Q1 2026 Earnings Call:

“China has a well-developed e-commerce infrastructure, high population density, and strong demand for service consumption, providing a solid foundation for the integration of our quick commerce business and the Taobao app. We believe this convergence will fulfill consumer needs for a one-stop consumption experience and meet merchants’ desire to serve consumers across multiple scenarios. It will enhance commerce efficiency and pave the way for an all-in-one AI assistant for consumption. Alibaba’s strategic positioning in quick Commerce has ambitions beyond competing in a single category.”

Mixed Q1

Alibaba entered fiscal 2026 on a mixed note — revenues grew 2% year-over-year to RMB247.7 billion, or $34.5 billion in the first quarter, while adjusted earnings declined by 10% to RMB14.75, or $2.06 per ADS. Revenue from the Alibaba China E-commerce Group segment was up 10% YoY, and International Digital Commerce Group revenue rose 19%. Cloud Intelligence Group revenue jumped 26% in Q1. Net income attributable to ordinary shareholders was RMB43.1 billion, or $6 billion, up 78% compared to last year. Earnings per ADS surged 82% from last year to RMB17.98, or $2.51.

The company has been actively investing in technology, particularly in AI, to drive growth across e-commerce, cloud computing, and other businesses. The e-commerce business got a major boost from the recent integration of AI into the platform, even as the broader industry is facing challenges like restrained consumer spending, increasing competition, and a complex regulatory environment.

The average price of Alibaba’s stock for the last 52 weeks is $124.23. On Tuesday, the stock opened slightly lower but soon gained momentum and was trading up 1.5% in the afternoon.

from NYSE Updates – Techyrack Hub https://ift.tt/BGK8i0M
via IFTTT

SUSS Microtec outlines growth strategy with three new segments

SUSS Microtec outlines growth strategy with three new segments

from NYSE Updates – Techyrack Hub https://ift.tt/1faZprA
via IFTTT

Dell to benefit from AI demand as new orders offset lower margin

Dell to benefit from AI demand as new orders offset lower margin

from NYSE Updates – Techyrack Hub https://ift.tt/y41ATnE
via IFTTT

Shutdown Squeeze: How Big Money is Forced to Sell

Listen up, folks—the government’s been dark for 37 days now, officially the longest shutdown in history, and Wall Street’s starting to sweat. As of this writing, with markets still finding their footing mid-morning, the real action isn’t in the headlines—it’s in the plumbing. Cash is vanishing faster than free samples at a bakery, and the heavy hitters—pensions, hedge funds, the whole institutional crew—are getting squeezed hard. We’re talking forced sales, margin headaches, and a liquidity crunch that’s turning the Treasury’s cash stash into a vacuum for everyone else. This isn’t just another D.C. drama. It’s a wake-up call that when spending stops, the money stops flowing—and someone’s got to pay the price.

The Cash Vacuum: What’s Draining the System?

Here’s the deal: The government’s main bank account—the Treasury General Account, or TGA—sits at the Federal Reserve like a giant sponge. Normally, it pulls in taxes and bond money, then pumps it right back out through paychecks, contracts, and all the spending that keeps things moving. But during a shutdown? Money keeps coming in—tax season doesn’t pause for politics—but the spending side freezes solid. As of October 30, 2025, that account crossed $1 trillion, up roughly $200 billion in just weeks. It dipped to $925 billion by November 3, but make no mistake—it’s still sky-high and sucking cash out of circulation.

That money isn’t landing in banks for loans, isn’t fueling money market funds, and definitely isn’t helping stock buyers chase the next big winner. It’s just sitting there, draining reserves from the banking system. Total bank reserves have been sliding toward $3.3 trillion, and short-term borrowing rates are jumping. The key overnight rate, SOFR, hit 4.22% amid recent pressures—way above normal. It’s like the Fed accidentally slammed on the brakes, even while talking about easing up to boost growth.

This is real. The Treasury Borrowing Advisory Committee noted on November 4 that the lack of economic data from the shutdown is already throwing off inflation bets and bond trading.¹ Wolf Street put it bluntly in their November 4 report: This TGA surge is “involuntary quantitative tightening on steroids,” pulling in $700 billion since the debt ceiling fight ended in July.² For regular people, that means tighter credit, higher costs to borrow, and a market that’s suddenly on edge.

History Check: What Past Shutdowns Teach Us

We’ve seen this movie before, and the script usually has a happy ending for stocks. Take 2013—16 days of budget gridlock over healthcare. The S&P 500? Up about 3.1%, barely blinked, thanks to steady jobs and calm rates.³ Then the monster: 2018-2019, 35 days of wall-to-wall fighting. Stocks didn’t just hang on—they gained around 10.3%, helped by the Fed flipping from rate hikes to cuts.⁴

LPL Financial looked at all 21 shutdowns since 1976 and found the average S&P return during them? Zero. Flat. But here’s the good part: Stocks rose in half the cases, and kept climbing three and six months later in most scenarios.⁵ Edward Jones says it best—markets “look through the noise” and focus on earnings and growth.⁵

But this time? It’s got a different vibe. Back then, the system had more cushion. Now, after years of the Fed shrinking its balance sheet, we’re starting leaner. The 2018 repo crisis comes to mind—rates spiked, the Fed jumped in fast. Reuters warned back in September that a long shutdown could leave regulators and data in the dark, making markets “fly blind.”⁶ If this stretches past mid-November, we might see those old stresses on steroids.

The Big Players: Getting Hit Where It Hurts

Now let’s talk about the pros—the pensions, insurers, and hedge funds managing trillions. When cash gets tight, they face margin calls: Lenders want more collateral or cold hard cash to back their positions. Can’t deliver? You sell. And fast.

Goldman Sachs flagged it early—systematic funds, those quant-driven machines, were down 1.8% in the first four days of October alone in a “textbook unwind.”⁷ JPMorgan estimates $25 to $40 billion in stock sales from automated strategies as volatility kicked in.⁸ Hedge funds have dumped $100 to $140 billion in Treasury basis trades—those bond-futures arbitrage plays—since early October, per trader commitment data.⁹

Bloomberg and FactSet show primary dealers cut Treasury holdings in recent weeks, with drawdowns fitting a $48 billion range amid balance sheet pressures.¹⁰ SEC rules require big hedge funds to report margin stress within 72 hours, and Q3 filings due mid-November are expected to show a pile-up.¹¹ Even real money accounts—like your 401(k) manager—are trimming top-quality bonds and steady stocks to build cash buffers. Banks are pulling back on lending to avoid overload.

It’s not chaos yet—reserves are still around $3.3 trillion—but it’s close. The Fed’s emergency lending facility took in about $50 billion at month-end October, a clear sign of strain.² Watch for the overnight cash pool dropping below $250 billion or that key rate topping 4.3%—those are flashing red lights for bigger sell-offs.

Market Ripples: Stocks, Gold, and Crypto Feel It

Markets hate surprises, and this squeeze is delivering. As of this writing, the S&P 500 is down about 2.3% since October’s close, Nasdaq off 1.9%, small caps around 1.3% lower.¹² Tech’s getting hammered—names like Nvidia (NVDA) and Meta (META) slipped on earnings misses, made worse by sellers needing cash fast. But not everything’s sinking: Utilities and consumer staples are holding up, as money shifts to safer spots.

Volatility’s up—the fear gauge hit nearly 20 last week—but that can mean chances for quick movers. Gold’s shining at around $3,989 to $4,014 per ounce recently, a go-to shield in uncertain times.¹³ Bitcoin (BTC-USD) has dropped 18% from its October peak to roughly $104,000, but analysts see a sharp bounce if spending restarts, flooding the system with cash.¹⁴

The risks are real: Goldman says each week of shutdown shaves about 0.15% off GDP, hitting small businesses and exporters hardest.¹⁵ Defense stocks might cushion some blows, but trade talk adds fog. On the flip side, earnings are still projected to grow 8 to 10% in 2025, and the Fed’s hinting at rate cuts despite the data gaps.¹⁶ For growth stocks, the squeeze caps upside; for steady names, it’s a chance to shine.

Looking Ahead: Weathering the Storm

Bottom line—this liquidity pinch is legit, echoing 2018’s repo mess but starting from a tighter spot. History shows the S&P averages 13% gains a year after shutdowns end.⁵ JPMorgan and Reuters warn that if no deal by November 15, the drag gets heavier—the Fed’s guessing on cuts without fresh numbers.¹⁷ The TGA at $925 billion on November 3 might be near a top, but another tax wave could refill it fast.²

Smart play? Spread out—lean into reliables, keep an eye on gold’s protection, and watch for crypto’s rebound. Washington’s battles come and go, but solid companies and innovation stick around. Stay liquid, stay alert, and don’t let the panic push you around. The market rewards patience. Until the lights come back on in D.C., keep your cool and your cash ready.

Word count: 1,142

Sources:
1. Treasury Borrowing Advisory Committee Minutes, Nov 4, 2025
2. Wolf Street, “TGA Refill Absorbs $700 Billion,” Nov 4, 2025
3. S&P 500 Historical Data, 2013
4. S&P 500 Performance, Dec 2018–Jan 2019
5. LPL Financial Shutdown Analysis, 2025
6. Reuters, “Markets Flying Blind,” Sep 30, 2025
7. Goldman Sachs Quant Note, Oct 7, 2025
8. JPMorgan Strategy Update, Oct 2025
9. CFTC Commitment of Traders Report
10. Bloomberg/FactSet Dealer Positioning
11. SEC Form PF Requirements
12. Market Data as of Nov 6, 2025
13. Gold Spot Prices, Nov 3–6, 2025
14. Yahoo Finance Crypto Analysis
15. Goldman Sachs Economic Impact Note
16. Consensus EPS Forecasts, 2025
17. JPMorgan Webinar, Oct 2, 2025

from NYSE Updates – Techyrack Hub https://ift.tt/IgrnKmk
via IFTTT

On Holding AG (NYSE: ONON): Premium Innovation as the Engine for Sustained Market Share Gains in Performance Running

On Holding AG (NYSE: ONON), the Swiss-based innovator in premium athletic footwear and apparel, has captured investor attention amid a volatile market for consumer discretionary stocks. Founded in 2010 by three Swiss ultrarunners, On has carved a niche in the performance running segment through its proprietary CloudTec cushioning technology—a pod-like sole system that delivers a responsive, cloud-like ride. With a market capitalization of approximately $11.5 billion and shares trading around $35 as of November 12, 2025, On operates in a fiercely competitive landscape dominated by giants like Nike and Adidas, yet it continues to outpace peers in growth metrics.Recent headlines underscore this momentum. On November 12, 2025, the company reported record third-quarter results, with net sales surging 24.9% year-over-year to CHF 794.4 million ($820 million), beating consensus estimates by over 5%. Adjusted EBITDA margins expanded to 22.6%, reflecting operational leverage, while the firm raised its full-year 2025 guidance to CHF 2.98 billion at current FX rates, implying at least 34% constant-currency sales growth. This comes after a period of share weakness, with ONON down nearly 36% year-to-date prior to the report, pressured by macroeconomic headwinds and tariff concerns. CEO Caspar Coppetti highlighted “strong momentum in the first days of November,” attributing gains to robust demand in the Americas and China, bolstered by high-profile partnerships like Zendaya’s endorsement.

These results are not mere quarterly noise but a validation of a deeper structural shift: On’s relentless focus on premium product innovation is positioning it to capture durable market share in the high-growth performance running category. This article posits a forward-looking investment thesis centered on that single fundamental driver—premium innovation as the catalyst for sustained 10-15% annual market share expansion in running footwear through 2030. More likely than not, this will drive ONON shares toward $60 within the next 12 months, implying 70% upside from current levels, as evidenced by historical analogues like Hoka’s ascent under Deckers Outdoor.

We will explore this thesis through four sections: an overview of the innovation edge and its historical precedents; supporting qualitative and quantitative evidence, including a discounted cash flow (DCF) valuation; key risks and counterarguments; and On’s positioning within the broader athletic footwear sector. This analysis draws on industry reports, peer benchmarks, and On’s financial disclosures to provide actionable insights for sophisticated investors.

The Innovation Thesis: Why Premium R&D Will Drive Market Share Dominance

At the heart of On’s outperformance lies its commitment to premium innovation, defined here as heavy R&D investment in proprietary technologies that command $150-$200 price points while delivering superior athlete feedback. Unlike broad-line incumbents chasing volume at lower ASPs (average selling prices), On targets the affluent, performance-obsessed runner willing to pay for marginal gains in speed, recovery, and sustainability. This focus is underexplored in current discourse, which often fixates on DTC channel shifts or macro consumer spending; yet, it represents the linchpin for long-term moat-building, as evidenced by On’s gross margins expanding to 65.7% in Q3 2025—well above the industry average of 45-50%.

Historically, brands excelling in this vein have reaped outsized rewards. Consider Hoka One One, acquired by Deckers Outdoor (NYSE: DECK) in 2013 for a modest sum. Hoka’s maximalist cushioning—much like On’s CloudTec—disrupted the running shoe market by addressing pain points in traditional designs, leading to strong post-acquisition revenue growth averaging 40-50% YoY in key years, with peaks exceeding 90%. Deckers’ stock surged over 1,000% from 2018-2023 as Hoka captured 5-7% U.S. running market share, per NPD Group data, validating the premium innovation playbook. On mirrors this trajectory: Since its 2021 IPO, R&D spend has averaged 4-5% of revenues (vs. Nike’s 2-3%), fueling launches like the Cloudboom Strike, a carbon-plated racer that shaved seconds off elite marathon times. The Q3 earnings lift guidance by 2-3 points, citing “technology-driven demand,” directly underscoring this as a catalyst accelerating share gains.

This thesis gains plausibility from industry trends: The global running shoes market is projected to reach approximately $17 billion in 2025, growing at a 5% CAGR through 2033, fueled by athleisure and wellness booms, with premium segments (ASP > $150) expanding twice as fast at 10%+. On’s 39% TTM revenue growth far exceeds Nike’s 2-3%, positioning it to echo Hoka’s path rather than Allbirds’ stumble— the latter faltered post-IPO with flat innovation, seeing shares crater 90% as it chased casual over performance.

Evidence Base: Qualitative Edge Meets Quantitative Tailwinds

Qualitatively, On’s innovation manifests in athlete endorsements and product virality. Partnerships with Zendaya and triathletes like Gustav Iden amplify brand cachet, driving 27% DTC growth in Q3—up from 20% prior—via immersive online experiences showcasing CloudTec’s biomechanics. This echoes Lululemon’s women’s athleisure pivot in the 2010s, where targeted innovation yielded 30%+ CAGR and a 500% stock run. Quantitatively, On’s metrics shine: 112% projected EPS growth to $1.56 in FY2025, ROIC at 6.58% (rising), and debt/equity of 0.39 signal efficient scaling. Peers like Deckers trade at 20x forward sales on 15% growth; On’s 3.66x P/S on 39% growth appears reasonable, per Finviz benchmarks.

To quantify the thesis, we apply a DCF valuation, chosen for its focus on free cash flow (FCF) generation from innovation-driven margins—ideal for a growth story like On. Assumptions: Base revenues at CHF 2.98B for 2025 (per guidance), 25% CAGR through 2028 tapering to 10% terminal (aligned with running market growth), EBITDA margins expanding to 25% by 2027 (from 22.6%), capex at 5% of sales, WACC of 9% (beta 2.18, risk-free 4%, equity premium 5%). This yields FCF of CHF 500M by 2028; discounting back plus terminal value (3% growth) implies enterprise value of $18.5B, or $62 per share—77% above spot. Sensitivity: A 20% growth shave drops fair value to $55; Hoka’s historical 25%+ CAGR post-innovation cycles validates the inputs. Weaknesses include FX volatility (On reports in CHF) and execution risk, but low debt mitigates. Independent models suggest a range of $39-65 per share, with analyst consensus at $62.

Competitively, On holds 2-3% global running share (vs. Nike’s 30%), but its 44% Q/Q sales growth dwarfs Adidas’ 5%, per Q3 previews. Among challengers, On’s premium ASP ($180 avg.) outstrips Hoka’s $160, enabling margin upside.

Risks and Counterarguments: Navigating Execution Hurdles

Skeptics may argue On’s 96x trailing P/E signals overvaluation, vulnerable to consumer pullback in a high-interest environment. Indeed, shares dipped 30% pre-Q3 on tariff fears under Trump policies, echoing 2018-2019 trade war drags on peers like Under Armour (down 50%). Counterfeiting erodes 21% of premium footwear value, per OECD, and Allbirds’ 90% post-IPO plunge illustrates innovation fatigue risks if CloudTec feels iterative.

Yet, historical data tempers these: Hoka navigated 2020 tariffs via supply chain diversification (now 60% Vietnam/Mexico), boosting margins 500bps; On’s 2.0x quick ratio and 31% insider ownership suggest resilience. Q3’s tariff-proof China growth (triple-digits) and one-off margin tailwinds fading to normalized 63% still support 20%+ EBITDA, per guidance. If growth slips to 15%, DCF fair value holds at $50—still 40% upside.

Sector Context: On’s Niche Amid Athleisure Expansion

The $138B athletic footwear market grows at 4% CAGR to 2034, with running shoes claiming 37% share and premium athleisure accelerating to 6.3% amid wellness trends. North America (36% share) favors innovators like On, where DTC penetration hit 40% vs. Nike’s 25%. Peers falter: Adidas’ running sales stagnated at 2% growth in 2024, ceding ground to challengers; Hoka’s 2022 70% surge prefigures On’s potential, with Deckers up 38% YTD 2024 on similar dynamics.

Macro tailwinds include urban fitness initiatives (e.g., India’s $25B walkability push by 2025), but On’s Europe/Asia exposure (50% sales) hedges U.S. slowdowns. Versus microcaps, On’s $11.5B cap and 7.65% short interest ensure liquidity, though beta 2.18 amplifies volatility.

Forward Outlook: Catalysts to Monitor for Thesis Validation

On Holding’s premium innovation thesis portends robust upside, with market share gains likely propelling revenues beyond 25% CAGR and shares to $60, consistent with analyst targets. Investors should track Q4 holiday DTC comps for sustained momentum, R&D announcements (e.g., next-gen CloudTec) as leading indicators, and APAC penetration amid easing tariffs. If margins hold 23%+ into 2026, the bull case strengthens; slippage below 20% warrants reevaluation.

This analysis is for informational purposes only and does not constitute investment advice. Trading involves substantial risk, and readers must conduct their own due diligence before making decisions. Past performance is no guarantee of future results. As of November 12, 2025.

Sources: Yahoo Finance (Q3 Earnings, link); Finviz (Financial Metrics, link); Seeking Alpha (Analogues, link); Custom Market Insights (Market Trends, link); Alpha Spread (DCF, link); Footwear News (Hoka Comparison, link); OECD (Counterfeiting, via Mordor).

from NYSE Updates – Techyrack Hub https://ift.tt/c1HiKkQ
via IFTTT

Applied Materials Q4 2025 Earnings Call: Listen Live and Follow Along with the Real-Time Transcript

Semiconductor technology company Applied Materials, Inc. (NASDAQ: AMAT) is expected to report its fourth-quarter 2025 results today after the closing bell.

---

Listen to Applied Materials’ Q4 2025 earnings call live and read the real-time transcript

---

The consensus earnings estimate for Q4 is $2.1 per share, which represents a decline from the $2.32/share profit reported in the fourth quarter of 2024. Analysts are looking for revenues of $6.67 billion for the October quarter, compared to $7.04 billion in the year-ago period.

In the third quarter of FY25, adjusted earnings rose to $2.48 per share from $2.12 per share in the prior year, exceeding expectations. Net income, on an unadjusted basis, was $1.78 billion or $2.22 per share in Q3. Net revenue rose to $7.30 billion in the third quarter from $6.78 billion in the corresponding period of the previous year.

The post Applied Materials Q4 2025 Earnings Call: Listen Live and Follow Along with the Real-Time Transcript first appeared on AlphaStreet.

from NYSE Updates – Techyrack Hub https://ift.tt/zOqnFyp
via IFTTT

Earnings Summary: Highlights of Tencent Music’s (TME) Q3 2025 report

Tencent Music Entertainment Group (NYSE: TME), a leading music streaming platform in China, on Wednesday reported financial results for the third quarter of fiscal 2025.

• Third-quarter revenues increased 20.6% year-over-year to RMB8.46 billion, primarily due to strong year-over-year growth in revenues from online music services
• Revenues from online music services were RMB6.97 billion, up 27.2% year-over-year; revenues from music subscriptions rose 17.2% to RMB4.50 billion
• Net income attributable to equity holders was RMB2.15 billion in Q3, representing a 36.0% year-over-year growth
• Earnings per ADS were RMB1.38 during the three months, compared to RMB1.01 in the prior-year quarter
• Monthly ARPPU grew to RMB11.9 in Q3 from RMB10.8 in the same period of fiscal 2024
• As of September 30, 2025, total cash, cash equivalents, term deposits, and short-term investments were RMB36.08 billion

from NYSE Updates – Techyrack Hub https://ift.tt/bifUd0v
via IFTTT

Elliott Management says size not a drag on performance

Elliott Management says size not a drag on performance

from NYSE Updates – Techyrack Hub https://ift.tt/8BbCHsp
via IFTTT

Earnings Summary: Constellation Energy reports Q3 2025 results

Constellation Energy Corporation (NASDAQ: CEG), a leading clean energy company, on Friday announced financial results for the third quarter of fiscal 2025.

• Q3 earnings, on a reported basis, decreased to $2.97 per share from $3.82 per share in the third quarter of 2024
• On an adjusted basis, operating earnings for the quarter increased to $3.04 per share from $2.74 per share last year
• In the September quarter, operating revenue remained broadly unchanged at $6.57 billion
• Net income attributable to shareholders was $930 million in Q3, vs. $1.20 billion in the prior-year period
• Total operating expenses rose to $5.48 billion in Q3 from $5.09 billion a year earlier
• The company narrowed its full-year 2025 adjusted operating earnings guidance range to $9.05-9.45 per share
• During the quarter, the Conowingo Dam received a water quality certification, clearing the way for its re-licensing and continued operation of the dam’s hydroelectric facility

from NYSE Updates – Techyrack Hub https://ift.tt/Wzp6f0q
via IFTTT

UPS, FedEx ground MD-11 fleets after deadly Louisville crash

UPS, FedEx ground MD-11 fleets after deadly Louisville crash

from NYSE Updates – Techyrack Hub https://ift.tt/mb7rEeH
via IFTTT

BIO-Key stock soars after securing major Middle East defense contract

BIO-Key stock soars after securing major Middle East defense contract

from NYSE Updates – Techyrack Hub https://ift.tt/DLUu9pF
via IFTTT

CHR Stock Explodes on Buyout Buzz: What Traders Need to Know

As of November 5, 2025, early trading.

Listen up, folks, because if you’re glued to the markets this morning, you’ve probably seen the fireworks. As of this writing on November 5, 2025, Cheer Holding (NASDAQ: CHR) is lighting up the board with a surge—up over 100% in early trading, with shares reaching as high as $0.31 from yesterday’s close around $0.136. That’s the kind of move that gets your attention, but let’s keep our feet on the ground and break down what’s behind it. Based on the substantial premium in these offers, CHR shares are likely to trend upward if a deal advances toward completion, though failure to materialize could drive them back down amid the usual volatility. This is a prime example of how news can shake up the markets, and it’s worth unpacking for anyone navigating these waters.

The Spark: Buyout Whispers Turn into Roars

Picture this: A tech company suddenly gets word of interest from potential buyers, each floating a price that could reshape its future. That’s the story with Cheer Holding, which announced yesterday that its board received two preliminary, non-binding proposals to acquire all its outstanding Class A shares. One offer from Zhongsheng Dingxin Investment Fund Management comes in at $0.56 per share in cash, while Excel Ally Ventures is proposing $0.52 per share. These figures represent a substantial premium over recent trading levels—roughly four times the price from just days ago.

Important to note: These are early-stage overtures, not finalized agreements. They could evolve, fall through, or lead to even better terms if the company explores options. The board has wisely set up a special committee of independent directors to review the proposals, and they’re bringing in financial advisors and legal counsel to guide the process. Trading volume has spiked dramatically, hitting over 300 million shares already—far exceeding the typical daily average. This kind of activity shows how quickly investor interest can flood in on acquisition news, but it also highlights the market’s speculative nature.

Who Is Cheer Holding, Anyway?

Let’s pull back for a clearer view. Cheer Holding is a Beijing-based player in China’s fast-moving mobile internet space, focusing on innovative services that blend artificial intelligence, virtual reality, and blockchain to build engaging digital environments. Their offerings include video streaming platforms, e-commerce tools, live shopping features, and apps for social interaction and group purchases—all designed to connect users in seamless, tech-driven ways.

The company has been navigating some rough patches lately, with its stock hitting all-time lows amid broader pressures on small-cap and China-exposed names. But the fundamentals offer a steadier picture: For the first half of 2025, they reported revenues of $71 million and a net income of $7.8 million, translating to positive earnings per share. With $203.2 million in cash and equivalents, plus strong working capital of $284.5 million, they’ve got resources to fuel ongoing development in a digital economy that’s exploding with smartphone adoption and virtual experiences.

Why Buyout Talk Can Drive Sharp Increases (With a Catch)

Zooming out to the bigger market picture, acquisition rumors like these are a classic catalyst for price jumps. When word spreads of potential buyers circling, shares often climb as investors speculate on the premium a deal might bring. It’s a pattern we’ve seen play out across sectors—sudden interest can value a company far above its day-to-day trading level, reflecting hopes for a smooth transaction.

That said, the market’s enthusiasm comes with built-in cautions. These proposals are non-binding, meaning negotiations could stall over valuation disagreements, regulatory hurdles—particularly for a China-based firm—or shifting priorities from the bidders. History is full of deals that looked promising on paper but evaporated, leaving stocks to retrace their steps sharply. Add in factors like currency fluctuations, geopolitical tensions, and the inherent volatility of smaller companies, and it’s clear why thorough due diligence is key. The benefits of such events? They spotlight undervalued assets and can accelerate strategic growth. The risks? Heightened uncertainty and the potential for quick reversals that test even seasoned portfolios. Diversification and a long-term lens help weather these storms.

Trading Lessons from Today’s Wild Ride

Moments like this CHR surge are more than headline grabbers—they’re real-world classrooms for traders at any level. They illustrate how external events can override fundamentals in the short term, driving home the need to stay plugged into news flows without getting swept up in the hype. Key takeaways: Scrutinize announcements for the fine print, balance optimism with realism about deal probabilities, and always factor in broader risks like regulatory scrutiny in international markets.

At the end of the day, the markets reward those who approach opportunities with clear eyes—celebrating the insights gained from ups and downs alike. Cheer Holding’s story is still developing, and whatever the outcome, it’s a reminder that informed patience often trumps reactive moves.

Disclaimer: This article is for informational and educational purposes only and does not constitute investment advice, recommendations to buy or sell any security, or any other form of financial advice. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Investing involves risk, including the possible loss of principal.

from NYSE Updates – Techyrack Hub https://ift.tt/XszqOd7
via IFTTT

Tactile Systems Technology (TCMD): Patent-Driven Innovation Poised to Unlock Lymphedema Market Share Gains

Tactile Systems Technology, Inc. (NASDAQ: TCMD), a medical technology company specializing in at-home therapies for chronic conditions like lymphedema and airway clearance, has long operated in a niche but underserved segment of the healthcare market. With a market capitalization of approximately $336 million and shares trading around $15.77 as of November 3, 2025, TCMD remains a small-cap player with significant growth potential.

Recent headlines underscore this momentum. On November 3, 2025, Tactile Medical reported third-quarter financial results that exceeded expectations, with total revenue surging 17% year-over-year to $85.8 million and net income climbing to $8.2 million from $5.2 million in the prior year. The company raised its full-year 2025 revenue guidance to $317–$321 million (implying 8–10% growth) and adjusted EBITDA to $38–$39.5 million, while announcing a $25 million share repurchase program signaling confidence in its valuation. These results, driven partly by strong adoption of its AffloVest airway clearance system, also highlighted progress in lymphedema products like the Nimbl platform, which received FDA clearance for upper extremity use in 2024 and commercial launch for lower extremity expansion in October 2024.

While these developments provide a timely catalyst, they are symptomatic of a deeper, underappreciated fundamental shift at TCMD: the strategic buildup of its patent portfolio around proprietary pneumatic compression technologies. This intellectual property (IP) moat, encompassing a robust collection of issued and pending U.S. patents—including a 2018 acquisition of 31 related to pneumatic compression from Wright Therapy Products—positions TCMD to capture disproportionate share in the expanding lymphedema treatment market, projected to grow from $0.95 billion in 2025 to $1.46 billion by 2030 at a 9% CAGR (Mordor Intelligence). Our thesis posits that TCMD’s IP-driven product leadership will enable it to outpace market growth by 5–7 percentage points annually through 2030, driving revenue to $450–$500 million and supporting a re-rating to 4x sales multiples—implying 50–75% upside from current levels. This forward-looking view draws on historical precedents in medtech where strong IP portfolios catalyzed sustained outperformance.

In this analysis, we first outline the thesis in detail, supported by industry trends and analogues. We then dissect the qualitative and quantitative underpinnings, including a peer-relative valuation. Risks and counterarguments follow, contextualized within TCMD’s competitive landscape. Finally, we conclude with key monitors for investors.

The Core Thesis: IP Leadership as the Engine of Lymphedema Dominance

TCMD’s investment case hinges on a single, underexplored fundamental: its fortified patent portfolio, which creates a durable barrier to entry and fuels iterative product enhancements tailored to patient and payer needs. Unlike broader macro tailwinds like aging demographics, this factor is company-specific, leveraging TCMD’s 20+ years of R&D in pneumatic compression devices—non-invasive, at-home systems that outperform traditional manual therapies in efficacy and compliance.

Why does this matter? The lymphedema market remains fragmented, with compression garments and basic pumps dominating 70% of treatments, yet failing to address adherence issues (e.g., studies show BCRL self-care adherence often below 50% for modalities like manual lymphatic drainage; PMC study). TCMD’s patents cover advanced features like adaptive pressure algorithms in Nimbl, which improve patient outcomes based on clinical evidence from related Flexitouch trials presented at ASCO 2025. This IP edge enables premium pricing (gross margins at 76% in Q3 2025) and shields against commoditization.

Evidence of likelihood comes from industry trends: The pneumatic compression segment is forecast to grow at 6.09% CAGR through 2030, outstripping the overall market due to rising cancer survivorship (lymphedema affects 20–40% of breast cancer patients; IMARC Group). TCMD’s recent Q3 momentum—3–4% lymphedema growth guidance for 2025—underscores this, as FDA approvals and payer policy shifts (e.g., NCD reclassification of head/neck lymphedema) accelerate adoption. Analyses of patent-heavy medtech innovators indicate that firms with robust IP can achieve significant market share gains within 3–5 years of key launches (GreyB).

A compelling analogue is Boston Scientific’s (BSX) ascent in the 2000s. Following its 2001 acquisition of Target Therapeutics for $1.1 billion—which bolstered its neurovascular IP—BSX experienced accelerated innovation and 15% annual revenue growth through 2006 amid a similar fragmented interventional device market. Shares compounded at 25% CAGR, re-rating from 3x to 6x sales as IP translated to 20%+ market share gains. TCMD mirrors this: Its patents (e.g., on compression garment systems and methods; Justia Patents) deter rivals like Bio Compression Systems, which lack comparable direct-sales IP and efficacy data. With TCMD’s sales force expanding to 329 reps (up 15% Y/Y), we expect analogous share gains, targeting 25% of the U.S. pneumatic segment by 2028.

Qualitative and Quantitative Underpinnings: Building the Case for Acceleration

Qualitatively, TCMD’s IP fosters a virtuous cycle: Superior devices drive clinical evidence, unlocking reimbursement (e.g., 80% Medicare coverage for Flexitouch post-2024 NCD), which boosts adoption and funds further innovation. The Q3 news amplifies this, with Nimbl’s lower-extremity expansion tapping a significant underserved pool among the estimated 16 million U.S. lymphedema patients. Patient apps like Kylee, integrated via patented telemetry, enhance engagement and compliance, as evidenced by user feedback in company trials.

Quantitatively, TCMD’s metrics validate the thesis. TTM revenue of $299 million reflects 8% growth, with EPS at $0.62 and ROE at 7.64%—solid for a growth medtech but undervalued at 1.2x EV/sales versus peers’ 3–4x (e.g., Wright Medical at 3.5x pre-acquisition). Forward EPS growth of 44% (per analyst consensus) supports our projection: Assuming 12–14% revenue CAGR (5pp above market, per IP analogue), EBITDA margins expand to 15% by 2028 via scale.

For valuation, we apply a discounted cash flow (DCF) model, chosen for its focus on free cash flow (FCF) projections tied to IP-driven growth—superior to multiples alone for small-caps with lumpy earnings. Inputs: 12% WACC (beta 1.2, reflecting medtech volatility); terminal growth 4% (below GDP, conservative); FCF margin ramping from 8% to 12%. This yields $24–$28 per share (50–75% upside). Weaknesses include sensitivity to reimbursement changes (10% FCF drop if delayed), but historical peers like Medtronic (strong IP in pacemakers) sustained 15% FCF growth post-patent wins, mitigating this. Cross-checked against BSX’s 2001–2006 multiples (rising 2x on IP catalysts), TCMD’s current 16.6x forward P/E aligns with undervaluation.

Among competitors—Bio Compression (private, estimated ~$50M revenue, no IP depth), Devon Medical (~$30M, distributor-reliant), and larger peers like Arjo (~$1.1B, diversified)—TCMD’s direct-sales model and 76% gross margins eclipse averages (60% for peers; Simply Wall St). Sector-wise, medtech’s 4.4% CAGR (vs. TCMD’s projected 12%) favors niches like lymphedema, where IP leaders have historically demonstrated outperformance.

Risks and Counterarguments: Navigating the IP Moat’s Vulnerabilities

No thesis is ironclad; detractors might argue TCMD’s IP, while strong, faces expiration risks (e.g., core Flexitouch patents expired in 2017, with follow-on protections extending into the 2030s) and competitive encroachment from low-cost imports. Q3’s noted dip in commercial lymphedema sales highlights payer pushback on head/neck classifications as “experimental,” potentially capping near-term growth at 5%.

Yet, historical analogues temper these. Boston Scientific weathered patent cliffs in the 2010s via follow-on filings, sustaining 10% growth; TCMD has continued aggressive IP development, including recent acquisitions and applications. Industry data shows IP-heavy firms like Stryker (CII score 168, top-decile) maintain high patent activity, supporting sustained competitive advantages (MD+DI). Liquidity risks are minimal (current ratio 3.79, debt-to-equity 0.11), and the $25M buyback provides a floor. Overall, risks cap downside at 20%, far outweighed by 50%+ upside probability.

Sector Context: TCMD’s Niche Edge in a Maturing Medtech Landscape

Within the $548 billion medtech sector (4.4% CAGR; Fortune Business Insights), TCMD’s focus on chronic care devices aligns with tailwinds like value-based reimbursement, favoring at-home solutions (significant market share gains since 2020). Peers like 3M (diversified, 2x sales multiple) lag in lymphedema specificity, while TCMD’s 3-year return aligns with the XBI biotech index’s performance over the same period.

Macro headwinds—inflation eroding margins (up 100bps Y/Y)—are offset by TCMD’s pricing power from IP exclusivity. Historically, post-recession medtech (2009–2012) saw IP leaders like Medtronic gain 15% share as payers prioritized efficacy, a pattern repeating in 2025’s cost-conscious environment.

Forward Guidance: Catalysts and Vigilance for Investors

TCMD’s IP thesis supports a trajectory of sustained appreciation, with revenue acceleration to 15%+ in 2026–2027 as Nimbl penetrates lower extremities and international expansion (e.g., potential Europe via CE Mark) adds meaningful revenue. Watch Q4 earnings for sales force productivity (target 10% QoQ growth) and payer wins on head/neck coverage—key inflection points. Longer-term, monitor patent grants and M&A interest, as strong IP often precedes takeouts at 4–5x sales (e.g., Wright Medical to Stryker at 3.5x).

For sophisticated investors, TCMD offers a compelling asymmetry: Undervalued entry into a high-conviction growth niche. Do your own due diligence and position accordingly, but remain attuned to reimbursement evolution.

This analysis is for informational purposes only and does not constitute investment advice. Trading involves substantial risk, and readers should conduct their own due diligence before making decisions.

from NYSE Updates – Techyrack Hub https://ift.tt/ANyw8q5
via IFTTT

Earnings Summary: Loews Corporation (L) reports Q3 fiscal 2025 results

Loews Corporation’s (NYSE: L) subsidiary CNA Financial Corporation on Monday announced results for the third quarter of fiscal 2025.

• Third quarter-2025 net income rose to $403 million or $1.48 per share from $283 million or $1.04 per share in the prior-year quarter
• Core income for the quarter rose to a record high of $409 million or $1.50 per share from $293 million or $1.08 per share in the prior year quarter
• Net investment losses for the quarter were $6 million, compared to $7 million in the comparable period last year
• CNA Financial declared a quarterly dividend of $0.46 per share, payable on December 4, to stockholders of record on November 17
• The company appointed Douglas Worman as chairman of the board, in addition to his current responsibilities as president & chief executive officer, effective January 1, 2026

from NYSE Updates – Techyrack Hub https://ift.tt/X2PTnjY
via IFTTT

Earnings Summary: Highlights of LyondellBasell’s Q3 2025 report

LyondellBasell Industries (NYSE: LYB), a leading chemical company that produces polymers, has reported operating results for the third quarter of fiscal 2025.

• On a reported basis, the company posted a net loss of $890 million or $2.77 per share for Q3, vs. earnings of $573 million or $1.75 per share in the prior-year quarter.
• On an adjusted basis, it was a profit of $330 million or $1.01 per share in the September quarter, compared to $626 million or $1.91 per share last year
• EBITDA was a loss of $480 million in the third quarter, vs. a positive EBITDA of $1.17 billion in the year-ago quarter
• Q3 sales and operating revenues decreased to $7.73 billion from $8.6 billion in Q3 2024
• The company reported cash from operating activities of $983 million for the quarter; it returned $443 million to shareholders through dividends
• The management expects year-end seasonality and lower operating rates to impact Q4 results across most businesses

from NYSE Updates – Techyrack Hub https://ift.tt/P4dw3y7
via IFTTT

Nexperia’s Dutch headquarters says it welcomes announcements lifting block on shipping chips

Nexperia’s Dutch headquarters says it welcomes announcements lifting block on shipping chips

from NYSE Updates – Techyrack Hub https://ift.tt/uJhTNAp
via IFTTT

AlphaTON Capital Corp. (ATON): TON Ecosystem Exposure as a Gateway to Explosive Decentralized AI Growth

Introduction

AlphaTON Capital Corp. (NASDAQ: ATON), a micro-cap digital asset treasury company with a laser focus on The Open Network (TON) blockchain and the Telegram ecosystem, is carving out a niche at the intersection of crypto infrastructure and artificial intelligence. On October 29, 2025, AlphaTON announced a strategic investment in high-performance GPU infrastructure to power Cocoon, Telegram’s newly unveiled Confidential Compute Open Network—a decentralized AI inference platform set to launch in November. This move, involving substantial deployment of GPUs and data centers, not only bolsters AlphaTON’s TON token reserves but also positions it as an early infrastructure provider in a privacy-centric AI network backed by Telegram’s billion-plus users.

While the announcement highlights AlphaTON’s commitment to ecosystem development, it acts as a catalyst for a broader, underexplored fundamental shift: AlphaTON’s deep integration into the TON ecosystem will enable it to capture outsized value from the convergence of blockchain and decentralized AI, driving TON-denominated revenue growth of 50%+ annually through 2027 and transforming its balance sheet from a speculative treasury to a high-yield infrastructure play. This thesis moves beyond generic crypto exposure narratives, emphasizing AlphaTON’s unique role in TON’s AI infrastructure layer amid limited public-market proxies for this trend. The following sections unpack the thesis through historical analogues, quantitative projections, competitive dynamics, and risk evaluation.

The Core Thesis: TON Integration as AlphaTON’s Yield-Generating Moat

AlphaTON’s strategic pivot to TON-focused infrastructure, including staking, validation, and now GPU provisioning for AI networks like Cocoon, creates a self-reinforcing moat that leverages Telegram’s user base for recurring, token-denominated yields. Unlike passive holders, AlphaTON actively deploys capital into ecosystem projects, earning TON rewards that compound with network growth—projected to yield 10-15% APY on its $100 million+ TON reserves by 2026, combining base staking rates of 4-6% with GPU compute incentives.

The Cocoon investment exemplifies this: By supplying GPUs for confidential AI inference, AlphaTON secures priority access to compute rewards in TON, aligning incentives with developers building on Telegram’s platform. This isn’t mere speculation; it’s a bet on TON’s evolution from a payments layer to an AI powerhouse, where infrastructure providers like AlphaTON capture fees from a network handling millions of daily queries. Industry reports forecast the blockchain AI market to grow from approximately $562 million in 2024 to over $3.4 billion by 2032, with decentralized compute comprising a significant share as privacy demands escalate. TON, with its 141 active projects and 78% developer growth in 2024, is primed to lead this, per Everstake’s 2025 blockchain trends.

Historical analogues validate the likelihood: During the 2021 bull market, Galaxy Digital (GLXY.TO) surged 1,200% by investing in Solana’s early infrastructure, mirroring AlphaTON’s TON focus but with AI upside. Similarly, Bitfarms (BITF) transitioned from mining to high-performance computing in 2024, delivering 400% gains amid AI hype. AlphaTON, trading at a 40% discount to its TON NAV, could follow suit as Cocoon’s November launch accelerates adoption, shedding light on an under-discussed angle: public equities as proxies for niche L1 ecosystems like TON, where AI integration remains overlooked versus Solana or Ethereum.

Quantitative and Qualitative Underpinnings: Projecting Value Accrual

Quantitatively, AlphaTON’s $33 million market cap undervalues its $100 million TON holdings (at $2.26/TON), implying a 3x premium potential as yields materialize. A sum-of-the-parts valuation—assigning 1.5x NAV to TON assets ($150 million) plus 5x forward EBITDA to infrastructure ($50 million by 2027)—suggests $12 per share, a 130% upside from $5.22. This DCF variant uses a 25% discount rate for crypto volatility, 50% revenue CAGR from GPU fees (benchmarking Render’s RNDR 300% growth in 2024), and 5% terminal yield; its rationale suits micro-caps with asset-heavy models, though weaknesses include TON price sensitivity (mitigated by 10-15% APY staking floor). Tested against Galaxy’s 2021 multiples (4x NAV peak), it aligns with bull-market reflexivity.

Qualitatively, AlphaTON’s TON treasury—bolstered by $30 million acquisitions in September—positions it as a “digital asset treasury company” (DATCO) with AI differentiation. Cocoon’s model, rewarding GPU providers with TON for private inference, taps Telegram’s 1 billion users for demand, much like Bittensor (TAO) democratized ML models on blockchain. AlphaTON’s CEO Brittany Kaiser’s background in blockchain policy enhances partnerships, echoing Galaxy’s institutional pivot that drove 12% weekly gains in September 2025. Compared to peers, AlphaTON’s pure TON play (95% exposure) outpaces diversified firms like Hut 8 (HUT), whose YTD +150% lags Bitfarms’ AI pivot (+400% from September lows).

In the $826 billion AI market by 2030 (Statista), decentralized subsets like Cocoon address centralization risks, with AlphaTON’s low debt/equity (0.02) enabling aggressive capex. This setup, per McKinsey’s $15.7 trillion AI economic add by 2030, favors infrastructure enablers over pure plays.

Risks and Counterarguments: Balancing Volatility with Resilience

Critics may contend that AlphaTON’s micro-cap status ($33 million) exposes it to extreme volatility, with 3Y returns down 96% reflecting crypto drawdowns and execution risks in unproven networks like Cocoon. TON’s reliance on Telegram invites regulatory scrutiny—Pavel Durov’s 2024 arrest unified the community but highlighted geopolitical vulnerabilities—potentially capping growth if EU probes intensify. Moreover, GPU investments face competition from Render or Akash, diluting yields if adoption lags.

Yet, historical data counters these: Galaxy Digital rebounded 300% post-2022 crash via ecosystem bets, while Bitfarms’ HPC shift yielded 400% despite 40% pullbacks. AlphaTON’s $0.28/share cash buffer and 78% EPS Q/Q improvement signal resilience, with TON’s 141 projects (up from 2024) providing diversification. Regulatory tailwinds, like the U.S. GENIUS Act for stablecoins, indirectly bolster TON’s payments layer, mitigating downside to 20-30% in bear scenarios per Galaxy’s Q2 2025 VC report. Execution risks are real but lowered by partnerships, as seen in Morpheus AI’s October tie-up.

Sector and Macro Context: AlphaTON in the AI-Crypto Nexus

Amid a $391 billion AI market exploding to $1.81 trillion by 2030 (Founders Forum), AlphaTON thrives in the underexplored decentralized AI niche, where blockchain solves centralization woes. TON’s 2025 projections—$30/TON price (Metalamp) and DeFi/GameFi boom—align with a16z’s 100x throughput gains, positioning AlphaTON ahead of peers like HIVE (crypto mining focus). The sector’s 27.67% CAGR (Statista) favors TON’s Telegram integration, with Cocoon echoing Solana’s 78% developer surge but with privacy edge.

Macro shifts, including AI’s $15.7 trillion GDP boost (McKinsey), amplify this: As 80% of enterprises adopt GenAI by 2026 (Gartner), decentralized compute via TON fills gaps in data sovereignty. Peers like Galaxy (GLXY) outperformed in 2021 bulls (+1,200%), a precedent for AlphaTON as TON captures 10-15% of AI-crypto flows.

Conclusion

AlphaTON Capital Corp.’s TON ecosystem entrenchment, amplified by GPU plays like Cocoon, forges a compelling path to yield-driven appreciation in a decentralized AI landscape. As TON scales with Telegram’s user flywheel, AlphaTON stands to convert holdings into operational alpha, potentially narrowing its NAV discount. Watch TON developer metrics above 200 projects and Cocoon GPU utilization over 50% as validation signals; persistent crypto volatility warrants caution, but the thesis points to structural upside.

This analysis is for informational purposes only and does not constitute investment advice. Trading involves substantial risk, and readers should conduct their own due diligence before making any decisions.

from NYSE Updates – Techyrack Hub https://ift.tt/WewA79J
via IFTTT

Visa reports higher Q4 revenue and profit; results beat estimates

Visa, Inc. (NYSE: V) on Tuesday reported an increase in revenues for the fourth quarter of fiscal 2025, which translated into a 10% growth in adjusted earnings.

Fourth-quarter revenue grew 12% annually to $10.7 billion, aided by an increase in payment volume amid continued healthy consumer spending. The top-line beat analysts’ estimates.

As a result, adjusted earnings rose to $2.98 per share in Q4 from $2.71 per share last year, exceeding expectations. On a reported basis, net income was $5.1 billion or $2.62 per share, vs. $5.3 billion or $2.65 per share reported in Q4 2024.

“We continued to invest in our Visa as a Service stack to serve as a hyperscaler across the payments ecosystem. As technologies like AI-driven commerce, real-time money movement, tokenization, and stablecoins converge to reshape commerce, our focus on innovation and product development positions Visa to lead this transformation,” said Ryan McInerney, Chief Executive Officer, Visa.

During the quarter, the company repurchased around 14 million shares of its common stock at an average cost of $349.77 per share for $4.9 billion.

from NYSE Updates – Techyrack Hub https://ift.tt/a4n3Sg5
via IFTTT

Earnings Summary: HCA Healthcare Q3 adj. profit jumps on strong revenue growth

Health services behemoth HCA Healthcare, Inc. (NYSE: HCA) has reported a sharp increase in adjusted earnings for the third quarter of fiscal 2025.

• Third-quarter revenues increased 9.6% year-over-year $19.16 billion
• Net income attributable to the company was $1.64 billion in Q3, up 29.4% from the prior-year quarter
• On a per-share basis, Q3 earnings jumped 42.6% annually to $6.96; adjusted earnings per share climbed 42% to $6.96
• Same facility admissions increased 2.1%, and same facility equivalent admissions moved up 2.4 YoY in Q3
• At $3.87 billion, third-quarter adjusted EBITDA was up 18.5% from the corresponding quarter last year
• Cash flow from operating activities was $4.42 billion in Q3, vs. $3.52 billion in Q3 2024
• The board declared a quarterly cash dividend of $0.72 per share, payable on December 29, 2025, to stockholders of record on December 15, 2025
• The management said it expects fiscal 2025 revenue to be in the range of $75.0 billion to $76.5 billion
• It is looking for full-year earnings per share in the range of $27.0 to $28.0

The post Earnings Summary: HCA Healthcare Q3 adj. profit jumps on strong revenue growth first appeared on AlphaStreet.

from NYSE Updates – Techyrack Hub https://ift.tt/eYRWafD
via IFTTT